[{"indications": "Indications\u00a0see under Dose", "name": "OMEPRAZOLE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "1 Gastro-intestinal system", "1.3 Antisecretory drugs and mucosal protectants", "1.3.5 Proton pump inhibitors", "OMEPRAZOLE"], "cautions": "Cautions\u00a0\n(From 1.3.5 Proton pump inhibitors: British National Formulary)\nCautions\u00a0Proton pump inhibitors may mask the symptoms of gastric cancer; particular care is required in those presenting with \u2018alarm features\u2019 (see Dyspepsia), in such cases gastric malignancy should be ruled out before treatment. A proton pump inhibitor should be prescribed for appropriate indications at the lowest effective dose for the shortest period; the need for long-term treatment should be reviewed periodically.; interactions: Appendix 1 (proton pump inhibitors)", "side-effects": "Side-effects\u00a0\n(From 1.3.5 Proton pump inhibitors: British National Formulary)\nSide-effects\u00a0Side-effects of the proton pump inhibitors include gastro-intestinal disturbances (including nausea, vomiting, abdominal pain, flatulence, diarrhoea, constipation), and headache. Less frequent side-effects include dry mouth, peripheral oedema, dizziness, sleep disturbances, fatigue, paraesthesia, arthralgia, myalgia, rash, and pruritus. Other side-effects reported rarely or very rarely include taste disturbance, stomatitis, hepatitis, jaundice, hypersensitivity reactions (including anaphylaxis, bronchospasm), fever, depression, hallucinations, confusion, gynaecomastia, interstitial nephritis, hyponatraemia, hypomagnesaemia (with long-term treatment), blood disorders (including leucopenia, leucocytosis, pancytopenia, thrombocytopenia), visual disturbances, sweating, photosensitivity, alopecia, Stevens-Johnson syndrome, and toxic epidermal necrolysis. By decreasing gastric acidity, proton pump inhibitors may increase the risk of gastro-intestinal infections (including Clostridium difficile infection).Rebound acid hypersecretion and protracted dyspepsia may occur after stopping prolonged treatment with a proton pump inhibitor.; also agitation and impotence", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/106487.htm", "doses": ["By mouth, benign gastric and duodenal\r\nulcers, 20\u00a0mg once daily for 4 weeks in duodenal ulceration or 8 weeks\r\nin gastric ulceration; in severe or recurrent cases increase to 40\u00a0mg\r\ndaily; prevention of relapse in gastric ulcer, 20\u00a0mg once daily, increased\r\nto 40\u00a0mg once daily if necessary; prevention of relapse in duodenal\r\nulcer, 20\u00a0mg once daily (range 10\u201340\u00a0mg daily)", "NSAID-associated duodenal or gastric ulcer and gastroduodenal\r\nerosions, 20\u00a0mg once daily for 4 weeks, continued for further 4 weeks\r\nif not fully healed; prophylaxis in patients with a history of NSAID-associated\r\nduodenal or gastric ulcers, gastroduodenal lesions, or dyspeptic symptoms\r\nwho require continued NSAID treatment, 20\u00a0mg once daily", "Duodenal or benign gastric ulcer associated with Helicobacter\r\npylori, see Recommended Regimens for Helicobacter pylori Eradication", "Zollinger\u2013Ellison syndrome, initially 60\u00a0mg once daily; usual\r\nrange 20\u2013120\u00a0mg daily (above 80\u00a0mg in 2 divided doses)", "Gastric acid reduction during general anaesthesia (prophylaxis\r\nof acid aspiration), 40\u00a0mg on the preceding evening then 40\u00a0mg 2\u20136\r\nhours before surgery", "Gastro-oesophageal reflux disease, 20\u00a0mg once daily for 4 weeks,\r\ncontinued for further 4\u20138 weeks if not fully healed; 40\u00a0mg once daily\r\nhas been given for 8 weeks in gastro-oesophageal reflux disease refractory\r\nto other treatment; maintenance 20\u00a0mg once daily", "Acid reflux disease (long-term management), 10\u00a0mg daily increasing\r\nto 20\u00a0mg once daily if symptoms return", "Acid-related dyspepsia, 10\u201320\u00a0mg once daily for 2\u20134 weeks according\r\nto response", "Severe ulcerating reflux oesophagitis, child over 1 year, body-weight 10\u201320\u00a0kg, 10\u00a0mg once daily increased if\r\nnecessary to 20\u00a0mg once daily for 4\u201312 weeks; body-weight over 20\u00a0kg,\r\n20\u00a0mg once daily increased if necessary to 40\u00a0mg once daily for 4\u201312\r\nweeks; to be initiated by hospital paediatrician", "By intravenous injection over 5 minutes or by intravenous infusion over 20\u201330 minutes,\r\nprophylaxis of acid aspiration [unlicensed indication], 40\u00a0mg completed\r\n1 hour before surgery", "Treatment and prevention of benign gastric ulcers, duodenal\r\nulcers, or NSAID-associated ulcers, gastro-oesophageal reflux disease,\r\n40\u00a0mg once daily until oral administration possible", "Zollinger-Ellison syndrome, initially 60\u00a0mg once daily, adjusted\r\naccording to response; daily doses above 60\u00a0mg given in 2 divided\r\ndoses", "Major peptic ulcer bleeding (following endoscopic treatment)\r\n[unlicensed indication], initial intravenous infusion of 80\u00a0mg over 40\u201360 minutes, then by continuous intravenous\r\ninfusion, 8\u00a0mg/hour for 72 hours (then change to oral therapy)", "Swallow whole, or disperse MUPS\u00ae tablets in water, or mix capsule contents or MUPS\u00ae tablets with fruit\r\njuice or yoghurt. Preparations consisting of an e/c tablet within\r\na capsule should not be opened"], "pregnancy": "Pregnancy\u00a0not known to be harmful"}]